European Medicines Agency Issues Restricted Indication for d4T (Stavudine)
The European Medicines Agency has completed a review of Zerit as part of the procedure for the renewal of the medicine's marketing authorisation.
The Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended that the marketing authorisation for Zerit should be renewed but that the use of the medicine should be severely restricted in both adults and children.
In this context:
Source: European Medicines Agency (EMA) (21.02.2011).
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 February 2011
A questions and answers document referring to this matter can be found in the following link:
Links to external websites are current at time of posting but not maintained.
This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)